Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ABP 938 · Ahzantive, Eylea

Fusion protein · Antagonist of Vascular endothelial growth factor-A (VEGFA) and Placental growth factor (PGF) · developed by Regeneron Pharmaceuticals

Approved FDA, Nov 2011
1 Registered trials

What is ABP 938?

Aflibercept-ayyh (Pavblu) is a soluble decoy receptor that binds vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF), inhibiting their activation of VEGF receptors on endothelial cells.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ahzantive, Eylea, Eylea Hd, Pavblu
Drug type
Fusion protein
Targets
Vascular endothelial growth factor-A (VEGFA), Placental growth factor (PGF)
Mechanism
Antagonist of Vascular endothelial growth factor-A (VEGFA) and Placental growth factor (PGF)
Pathways
angiogenesis, vascular permeability
Therapy area
Ophthalmology
Developer
Regeneron Pharmaceuticals
In trials of
AMGN
FDA status
Approved as Ahzantive, Eylea, Eylea Hd (November 18, 2011), BLA125387 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of May 10, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07614776 Phase 3 Neovascular Age-related Macular Degeneration Recruiting AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

nAMDNeovascular Age-related Macular Degeneration

Other drugs acting on VEGFA / PGF

Aflibercept FDA approved Bevacizumab FDA approved Ivonescimab Phase 3 Pumitamig Phase 2/3 Tovecimig Phase 2/3

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.